E Nvue Medical Holdings Corp
Total Consideration
$767.0K
ENvue Medical, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-29
Book Value Per Share
$53
Free Cash Flow Per Share
$-15
Cash Per Share
$7
Revenue Per Share
$4
OCF Per Share
$-15
Return on Equity
-106.6%
Return on Assets
-81.3%
Return on Invested Capital
-106.0%
Current Ratio
1.09
Quick Ratio
0.74
Asset Turnover
0.11
Days Sales Outstanding
41.32
Days Payables Outstanding
109.35
Days Inventory On Hand
355.42
Cash Conversion Cycle
287.39
R&D / Revenue
69.0%
SBC / Revenue
13.9%
Capex / Revenue
2.4%
Working Capital
$611K
Net Current Asset Value
$-356K
Invested Capital
$33M
OCF / Net Income
0.52
FCF / Net Income
0.52
Accruals Ratio (Sloan)
-21.4%
Net Debt
$-4M
Net Debt / EBITDA
0.19
Interest Coverage
-26.53
Cash Coverage
-18.64
Capex Coverage
-156.20
Tangible Common Equity
$35K
TCE / Total Assets
0.1%
Goodwill / Total Assets
70.7%
NOPAT
$-18M
Cash ROIC
-55.3%
WC / Revenue
23.9%
Capex / D&A
0.07
Reinvestment Rate
3.7%
Asset Growth vs Revenue Growth
1033.4%
Revenue 5Y CAGR
32.6%
Book Value 5Y CAGR
69.5%
Stock Price (FY-end)
$2
Market Cap
$1M
P/S Ratio
0.57
P/B Ratio
0.04
P/TB Ratio
41.48
Enterprise Value
$-3M
EV / Sales
-1.09
FCF Yield
-649.6%
Shareholder Yield
-20.3%
R&D Yield
121.4%
Capex Yield
4.1%
Shares Variation (YoY)
2229.2%
Beta (5Y)
0.78
Cost of Equity
8.4%
52W High
$78
52W Low
$2
Trailing Return 1Y
-96.4%
Trailing Return 5Y
-99.9%
F-Score (Piotroski)
2.00
Z-Score (Altman)
-4.72
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Stock Price on Earnings Dates
ENvue Medical, Inc. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 0.12% | 0.92% | -12.06% | 1.13% | 0.31% | 0.23% |
| Foreign Rate Differential | -0.08% | 0.02% | -0.03% | -0.10% | 0.04% | -0.17% |
| Other Adjustments | -1.39% | 0.86% | 0.09% | -0.01% | 0.30% | -0.47% |
| Valuation Allowance Change | -13.63% | -9.81% | -16.61% | -33.54% | -21.51% | -13.22% |
| Tax Law Change | — | — | — | — | — | — |
| Effective Tax Rate | -0.34% | -0.22% | -0.68% | 0.06% | -0.51% | 1.66% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $15.0K | $32.0K | $35.0K | $29.0K | $19.0K | −$307.0K |
| Income Taxes Paid (Cash) | — | — | — | — | — | $52.0K |
ENvue Medical, Inc. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.